BUDESONIDE / FORMOTEROL (Symbicort 100/3 pMDI®)

Clinical Indication

Asthma

Comments

– Restricted for use in children 12 to 17 years old with asthma in line with LLR guidelines when an aerosol device is required

– Children 5-11 years old only under secondary / tertiary asthma care where this may be started as MART regimen with spacer under specialist supervision. This can be continued in primary care.

COPD: Not licensed

In use shelf-life: 3 months

Date of classification

February 2026

Green

Medicines which could be started in any health care setting and do not require oversight by a specialist and which primary care would have full responsibility for prescribing and monitoring.